Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919621 | 0.83 | MEN1 (0.35) | NPSR1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL17784089 | 0.83 | MEN1 (0.35) | NPSR1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL17466785 | 0.82 | APLNR (0.33) | NPSR1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL20285870 | 0.81 | NPSR1 (0.34) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL19360780 | 0.81 | NPSR1 (0.34) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL11080010 | 0.80 | NPSR1 (0.36) | NPSR1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL25253736 | 0.79 | EPHX2 (0.34) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL21576490 | 0.79 | NPSR1 (0.33) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL20690392 | 0.79 | NPSR1 (0.33) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL19348570 | 0.79 | NPSR1 (0.33) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-120051470-A | Azaquinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| CN-118119595-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-115697969-A | 7-or 8-hydroxy-isoquinoline and 7-or 8-hydroxy-quinoline derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-114761405-A | anti-HBV 1, 7-naphthyridine compounds | 南京明德新药研发有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-10183928-B2 | Inhibitors of RET | BLUEPRINT MEDICINES CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170267661-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-09-21 | — | — | US | disclosed |
| US-20170267661-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-09-21 | — | — | US | disclosed |
| US-20170267661-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-09-21 | — | — | US | disclosed |
| WO-2017161269-A1 | INHIBITORS OF RET RECEPTOR TYROSINE KINASES | BLUEPRINT MEDICINES CORPORATION (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161269-A1 | INHIBITORS OF RET RECEPTOR TYROSINE KINASES | BLUEPRINT MEDICINES CORPORATION (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | NPSR1 4500/4885MEN1 4170/4885KMT2A 1676/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | NPSR1 2052/4885MEN1 2714/4885KMT2A 4396/4885 |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, MCL1, DTYMK | NPSR1 4500/4885MEN1 4170/4885KMT2A 1676/4885 |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDKN1A, CDK8 | NPSR1 4559/4885MEN1 1853/4885KMT2A 174/4885 |
| US-10183928-B2 | Inhibitors of RET | RET, HRAS, RB1 | NPSR1 3593/4885MEN1 376/4885KMT2A 491/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | NPSR1 864/4885MEN1 86/4885KMT2A 709/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | NPSR1 3277/4885MEN1 2199/4885KMT2A 3772/4885 |
| US-20170267661-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | NPSR1 3593/4885MEN1 376/4885KMT2A 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.